Clearside Biomedical, Inc. (CLSDQ)

Clearside Biomedical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6.8	20.02	28.92	48.26	30.44	17.29
Cash & Short-Term Investments	6.8	20.02	28.92	48.26	30.44	17.29
Cash Growth	-71.17%	-30.78%	-40.07%	58.56%	76.06%	-23.49%
Receivables	0.27	0.51	0.47	-	10	-
Prepaid Expenses	1.19	0.73	0.72	0.7	0.92	0.72
Restricted Cash	-	-	-	0.16	0.1	0.1
Other Current Assets	-	0.01	0.01	0.28	0.68	0.01
Total Current Assets	8.25	21.27	30.12	49.4	42.14	18.12
Property, Plant & Equipment	3.36	3.82	3.87	1.87	0.61	0.94
Other Long-Term Assets	0.03	0.03	0.03	0.03	0.16	0.26
Total Assets	11.64	25.13	34.02	51.3	42.9	19.32

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	0.8	1.45	2.21	1.05	0.94	2
Accrued Expenses	1.59	2.97	4.17	4.18	3.31	1.58
Current Portion of Long-Term Debt	-	-	-	-	-	0.99
Current Portion of Leases	0.38	0.38	0.36	0.35	0.39	0.37
Current Unearned Revenue	-	-	0.08	0.21	-	5
Total Current Liabilities	2.77	4.79	6.81	5.78	4.64	9.94
Long-Term Debt	61.17	51.77	41.99	33.98	-	-
Long-Term Leases	0.06	0.33	0.65	0.94	0.29	0.62
Other Long-Term Liabilities	1.59	7.09	0.48	-	-	-
Total Liabilities	65.59	63.98	49.93	40.7	4.93	10.56

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	0.08	0.08	0.06	0.06	0.06	0.05
Additional Paid-In Capital	319.94	316.34	304.95	298.98	293.41	264.58
Retained Earnings	-373.97	-355.28	-320.92	-288.44	-255.49	-255.87
Total Common Equity	-53.95	-38.86	-15.91	10.61	37.98	8.76
Shareholders' Equity	-53.95	-38.86	-15.91	10.61	37.98	8.76
Total Liabilities & Equity	11.64	25.13	34.02	51.3	42.9	19.32

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	61.61	52.47	43	35.26	0.68	1.98
Net Cash (Debt)	-54.81	-32.45	-14.08	13	29.76	15.31
Net Cash Growth	-	-	-	-56.33%	94.43%	-5.43%
Net Cash Per Share	-10.64	-6.60	-3.42	3.24	7.45	4.94
Filing Date Shares Outstanding	5.23	5.14	4.98	4.09	4.01	3.83
Total Common Shares Outstanding	5.23	5.11	4.19	4.04	3.98	3.46
Working Capital	5.48	16.48	23.31	43.62	37.5	8.18
Book Value Per Share	-10.31	-7.61	-3.80	2.62	9.54	2.53
Tangible Book Value	-53.95	-38.86	-15.91	10.61	37.98	8.76
Tangible Book Value Per Share	-10.31	-7.61	-3.80	2.62	9.54	2.53
Machinery	2.03	2.03	0.85	0.61	0.53	0.53
Construction In Progress	1.88	1.87	2.59	0.53	-	-
Leasehold Improvements	0.48	0.48	0.48	0.48	0.67	0.67

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 13, 2026

Data Sources Report a data error